Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy

被引:64
作者
Rudas, M
Filipits, M
Taucher, S
Stranzl, T
Steger, GG
Jakesz, R
Pirker, R
Pohl, G
机构
[1] Univ Vienna, Div Clin Oncol, Dept Med 1, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Pathol, A-1090 Vienna, Austria
[3] Univ Vienna, Dept Surg, A-1090 Vienna, Austria
基金
奥地利科学基金会;
关键词
breast cancer; chemotherapy response; multidrug resistance; neoadjuvant chemotherapy;
D O I
10.1023/A:1025751631115
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our purpose was to determine the expression of the drug resistance factors multidrug resistance protein (MRP1), lung resistance protein (LRP) and P-glycoprotein (Pgp) in breast carcinoma patients treated with preoperative chemotherapy. We have studied the expression of these proteins in breast carcinomas by immunohistochemistry both prior (n = 80) and after (n = 68) preoperative chemotherapy and compared their expression with response to preoperative chemotherapy. In paired samples prior and after chemotherapy expression of drug resistance factors was significantly lower in prechemotherapy samples as compared with postchemotherapy specimens. This was observed for MRP1 (62% vs. 88%, P < 0.001), LRP (65% vs. 97%, P < 0.001) and Pgp (55% vs. 100%, P < 0.001). Prechemotherapy expression of MRP1 was more frequently observed in patients with distant metastases than in those without (50% vs. 8%, P = 0.02). No associations were observed between LRP expression and clinical parameters. Pgp expression was more frequently detected in lobular carcinomas than in ductal carcinomas (93% vs. 46%, P = 0.001) and in patients with positive lymph nodes than in patients with negative lymph nodes (65% vs. 31%, P = 0.008) but was independent of other clinical parameters. No significant associations were found between the prechemotherapy or postchemotherapy expression of either of these three proteins and response to preoperative chemotherapy. However, prechemotherapy MRP1 expression was significantly associated with shorter progression-free survival of the patients (P = 0.02), whereas no such associations were observed for either LRP or Pgp. In conclusion, preoperative chemotherapy increases the expression of MRP1, LRP and Pgp. Response to chemotherapy is not associated with pre- or postchemotherapy expression levels of these drug resistance proteins but time to progression may be influenced by prechemotherapy MRP1 expression.
引用
收藏
页码:149 / 157
页数:9
相关论文
共 28 条
[1]   Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer [J].
Arnal, M ;
Franco, N ;
Fargeot, P ;
Riedinger, JM ;
Brunet-Lecomte, P ;
Lizard-Nacol, S .
BREAST CANCER RESEARCH AND TREATMENT, 2000, 61 (01) :13-20
[2]   Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].
Bonadonna, G ;
Valagussa, P ;
Brambilla, C ;
Ferrari, L ;
Moliterni, A ;
Terenziani, M ;
Zambetti, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100
[3]  
Chevillard S, 1996, CANCER, V77, P292, DOI 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO
[4]  
2-X
[5]   P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer [J].
Chung, HC ;
Rha, SY ;
Kim, JH ;
Roh, JK ;
Min, JS ;
Lee, KS ;
Kim, BS ;
Lee, KB .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 42 (01) :65-72
[6]  
Dexter DW, 1998, CLIN CANCER RES, V4, P1533
[7]  
Faneyte IF, 2001, INT J CANCER, V93, P114, DOI 10.1002/1097-0215(20010701)93:1<114::AID-IJC1309>3.3.CO
[8]  
2-A
[9]  
Filipits M, 1999, ANTICANCER RES, V19, P5043
[10]  
Filipits M, 1996, CLIN CANCER RES, V2, P1231